PNC-27 is a preclinical anticancer peptide
PNC-27 is a chimeric peptide containing a p53-derived HDM2-binding segment and a membrane-active leader sequence. It is an experimental laboratory compound, not an FDA-approved cancer drug or substitute for oncology care.
Evidence is limited to cells and animal models
Studies report that PNC-27 binds membrane-associated HDM2 and forms pores that lyse cultured cancer cells.[1] Related work has tested leukemia cell lines and mouse transplant models.[2] No human clinical trial establishes tumor response, survival, an effective dose, delivery to human tumors, or selectivity in patients.
There is no human safety profile
A membrane-disrupting mechanism raises unresolved off-target, immune, organ, interaction, and delivery risks. There is no human pharmacokinetic, adverse-event, pregnancy, combination-therapy, or long-term safety evidence. Using an unapproved peptide can also delay effective cancer treatment or affect clinical-trial eligibility.
Regulatory status
The National Cancer Institute dictionary describes potential antineoplastic activity, not approval.[3] PNC-27 remains preclinical and unapproved in the United States. Teloryx publishes no dose, cycle, or preparation protocol.